Abarelix
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Overview
Abarelix is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). It is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available. It belongs to the family of drugs called Gonadotropin-releasing hormone antagonists.
It is marketed by Speciality European Pharma as Plenaxis. Plenaxis has received marketing authorisation in Germany.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH